JavaScript 似乎在您的浏览器中禁用。 在我们的网站上获得最佳体验，请务必打开 Javascript 在您的浏览器。

为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验，建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?)，感谢您选择我们！

切换导航

我的购物车

搜索

首页
化学和生化试剂
砌块
有机砌块
3'-甲氧基苯甲酰甲基溴

3'-甲氧基苯甲酰甲基溴

规格或纯度: >98.0%

CAS编号: 5000-65-7
分子式: C₉H₉BrO₂
分子量: 229.07
Beilstein号: 8(4)337
MDL号: MFCD00000199
PubChem编号: 101294

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货	价格	数量
M158725-1g	1g	期货
M158725-5g	5g	现货
M158725-10g	10g	期货
M158725-25g	25g	现货
M158725-100g	100g	现货

查看相关系列

羰基化合物酮

Skip to the end of the images gallery

main product photo

Skip to the beginning of the images gallery

基本描述

别名	2-溴-3'-甲氧基苯乙酮
英文别名	2-Bromo-1-(3-methoxyphenyl)ethanone\|5000-65-7\|2-Bromo-3'-methoxyacetophenone\|3'-Methoxyphenacyl bromide\|m-Methoxyphenacyl bromide\|3-(Bromoacetyl)anisole\|2-Bromo-1-(3-Methoxyphenyl)Ethan-1-One\|Bromomethyl 3-methoxyphenyl ketone\|3-Methoxyphenacyl bromide\|MF
规格或纯度	>98.0%
英文名称	3'-Methoxyphenacyl Bromide
储存温度	2-8°C储存
运输条件	冰袋运输
产品介绍	2-bromo-3′-methoxyacetophenone, an alkylating agent, has been used to stabilize clopidogrel active metabolite (AM) in human plasma. It has also been used in the derivatisation of active metabolites in blood to ensure its stability during sample processing and storage. 2-bromo-3′-methoxyacetophenone, an alkylating agent, has been used to stabilize clopidogrel active metabolite (AM) in human plasma. It has also been used in the derivatisation of active metabolites in blood to ensure its stability during sample processing and storage.

名称和标识符

IUPAC Name	2-bromo-1-(3-methoxyphenyl)ethanone
INCHI	InChI=1S/C9H9BrO2/c1-12-8-4-2-3-7(5-8)9(11)6-10/h2-5H,6H2,1H3
InChi Key	IOOHBIFQNQQUFI-UHFFFAOYSA-N
Canonical SMILES	COC1=CC=CC(=C1)C(=O)CBr
Isomeric SMILES	COC1=CC=CC(=C1)C(=O)CBr
WGK Germany	3
PubChem CID	101294
UN Number	3261
Packing Group	II
分子量	229.07
Beilstein号	8(4)337
Reaxy-Rn	510128

化学和物理性质

溶解性	可溶于甲醇
熔点	60-62°C

安全和危险性（GHS）

象形图	Corrosive Harmful
信号词	Danger
危险声明	H319: Causes serious eye irritation H335: May cause respiratory irritation H314: Causes severe skin burns and eye damage
预防措施声明	P261,P305+P351+P338,P280,P321,P405,P501,P264,P260,P271,P301+P330+P331,P304+P340,P363,P403+P233,P264+P265,P305+P354+P338,P337+P317,P302+P361+P354,P316,P319
WGK Germany	3
Reaxy-Rn	510128
Class	8
个人防护装备	Eyeshields， Faceshields， full-face particle respirator type N100 (US)， Gloves， respirator cartridge type N100 (US)， type P1 (EN143) respirator filter， type P3 (EN 143) respirator cartridges

质检证书(COA)

质检报告(COA)

输入批号以搜索COA:

相关文档

质检报告COA

请输入批号:

SDS中文版 SDS英文版

质量技术规格说明书

产品问答

产品问答

登录提交问题

您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

参考文献

1. Nagy A Farid,Mary McIntosh,Fabio Garofolo,Ernest Wong,Amanda Shwajch,Monika Kennedy,Michelle Young,Pratibha Sarkar,Kiyoshi Kawabata,Makoto Takahashi,Henrianna Pang. (2006-12-13) Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry.. Rapid communications in mass spectrometry : RCM, 21 ((2)): (169-179). [PMID:17154350]
2. Miho Kazui,Katsunobu Hagihara,Takashi Izumi,Toshihiko Ikeda,Atsushi Kurihara. (2014-04-16) Hepatic microsomal thiol methyltransferase is involved in stereoselective methylation of pharmacologically active metabolite of prasugrel.. Drug metabolism and disposition: the biological fate of chemicals, 42 ((7)): (1138-1145). [PMID:24733788]
3. Zhe-Yi Hu,S Casey Laizure,Vanessa L Herring,Robert B Parker. (2014-04-25) Identification of alcohol-dependent clopidogrel metabolites using conventional liquid chromatography/triple quadrupole mass spectrometry.. Rapid communications in mass spectrometry : RCM, 28 ((11)): (1285-1292). [PMID:24760569]
4. Marta Karaźniewicz-Łada, Dorota Danielak, Błażej Rubiś, Paweł Burchardt, Grzegorz Oszkinis, Franciszek Główka,. (2014-05-02) The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.. Journal of clinical pharmacology, 54 ((8)): ( 874-880 ). [PMID:24782221]
5. K E Kristensen,H-J Zhu,X Wang,G H Gislason,C Torp-Pedersen,H B Rasmussen,J S Markowitz,P R Hansen. (2014-09-16) Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept study.. Clinical pharmacology and therapeutics, 96 ((6)): (713-722). [PMID:25222620]
6. H Zhang, D A Lauver, P F Hollenberg, . (2014-09-19) CYP-independent inhibition of platelet aggregation in rabbits by a mixed disulfide conjugate of clopidogrel.. Thrombosis and haemostasis, 112 ((6)): ( 1304-1311 ). [PMID:25230737]
7. Jinfang Jiang,Xiaoyan Chen,Dafang Zhong. (2017-12-07) Arylacetamide Deacetylase Is Involved in Vicagrel Bioactivation in Humans.. Frontiers in pharmacology, 8 (): (846-846). [PMID:29209217]
8. Ting Tai,Huan Zhou,Ting Zhu,Yu-Meng Jia,Jin-Zi Ji,Yi-Fei Li,Qiong-Yu Mi,Hong-Guang Xie. (2019-12-24) Development and validation of a UPLC-MS/MS method for simultaneous determination of vicagrel and its major metabolites in rat or human plasma: An optimized novel strategy for the stabilization of vicagrel.. Journal of pharmaceutical and biomedical analysis, 179 (): (112955-112955). [PMID:31866139]
9. Hongwei Yao,Jingkai Gu,Yuqin Shan,Yani Wang,Xue Chen,Dong Sun,Yingjie Guo. (2020-07-13) Type 2 diabetes mellitus decreases systemic exposure of clopidogrel active metabolite through upregulation of P-glycoprotein in rats.. Biochemical pharmacology, 180 (): (114142-114142). [PMID:32653591]
10. Makoto Takahashi,Henrianna Pang,Kiyoshi Kawabata,Nagy A Farid,Atsushi Kurihara. (2008-10-03) Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS.. Journal of pharmaceutical and biomedical analysis, 48 ((4)): (1219-1224). [PMID:18829199]
11. Bogumił Ramotowski,Paul A Gurbel,Udaya Tantry,Jan S Bracha,Marta Karaźniewicz-Łada,Zbigniew Lewandowski,Andrzej Budaj. (2020-01-16) Effect of Smoking Cessation on the Pharmacokinetics and Pharmacodynamics of Clopidogrel after PCI: The Smoking Cessation Paradox Study.. Thrombosis and haemostasis, 120 ((3)): (449-456). [PMID:31940672]
12. Jin-Zi Ji,Yi-Fei Li,Li-Ping Jiang,Ting Tai,Peng-Xin Ge,Qiong-Yu Mi,Ting Zhu,Hong-Guang Xie. (2020-11-03) P-glycoprotein deficiency enhances metabolic activation of and platelet response to clopidogrel through marked up-regulation of Cyp3a11 in mice: Direct evidence for the interplay between P-glycoprotein and Cyp3a.. Biochemical pharmacology, 183 (): (114313-114313). [PMID:33137324]

上海阿拉丁生化科技股份有限公司

销售条款及条件隐私政策

© 2016 ALADDIN-E.COM . 版权所有,未经授权禁止拷贝本站资料,如有违反,将追究法律责任

沪公网安备 31012002004058号沪ICP备09093490号-2

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用。

危险品化学品经营许可证（带存储）

营业执照(三证合一)